Long-term follow-up of kidney transplant recipients admitted to a tertiary care transplant center with SARS-CoV-2

Table 2 Outcomes, n (%)

Characteristics	ICU admission	Non-ICU admission	P value
Respiratory symptoms for admission	15 (71)	49 (65)	0.6
Mean hospital length of stay (days)	21.8 ± 19.4	8.6 ± 9.8	< 0.001
Use of remdesivir for management of SARS-CoV-2	5 (24)	23 (31)	0.54
Serum creatinine at time of SARS-CoV-2 infection (mg/dL)	1.91 ± 0.25	2.50 ± 2.17	0.002
Serum eGFR at the time of SARS-CoV-2 infection (mL/m2)	48.1 ± 24.6	37.9 ± 21.1	0.34
Serum creatinine 1-month post SARS-CoV-2 infection (mg/dL)	1.22 ± 0.29 (n = 6)	1.86 ± 1.47 (n = 66)	0.12
Serum eGFR 1 month SARS-CoV-2 infection (mL/m2)	73 ± 30.7	46.4 ± 21.7	0.18
Serum creatinine 6 months post SARS-CoV-2 infection (mg/dL)	1.34 ± 0.62 (n = 5)	1.67 ± 0.72 (n = 62)	0.86
Serum eGFR 6 months SARS-CoV-2 infection (mL/m2)	67.0 ± 32.8	47.0 ± 19.5	0.07
Serum creatinine 1 year post SARS-CoV-2 infection (mg/dL)	1.32 ± 0.70 (n = 4)	1.93 ± 1.21 (n = 61)	0.39
Serum eGFR 1 year post SARS-CoV-2 infection (mL/m2)	70.3 ± 34.9	44.3 ± 20.8	0.09
Serum creatinine at last follow-up (mg/dL)	1.29 ± 0.84 (n = 4)	1.88 ± 1.30 (n = 53)	0.5
Serum eGFR at last follow-up (mL/m2)	76.8 ± 37.0	48.1 ± 21.9	0.1
Uncensored graft failure at last follow-up	17 (81)	23 (31)	< 0.001
Death at last follow-up	16 (76)	13 (17)	< 0.001
Death related to COVID-19	15 (71)	4 (5)	< 0.001

COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; eGFR: Estimated glomerular filtration rate; ICU: Intensive care unit.